Table 1.
Clinical, Pathological, and Molecular Characteristics of the Patient Cohorts
| Tumor variable | Positive tumors (%) | Negative tumors (%) | Missing samples |
|---|---|---|---|
| Menopausal status | |||
| Premenopausal | 70 (23.7%) | ||
| Postmenopausal | 218 (73.9%) | ||
| Oophrectomy | 7 (2.4%) | ||
| Missing | 20 | ||
| Treatment | |||
| Simple mastectomy | 53 (16.8%) | ||
| Modified radical mastectomy | 262 (83.2%) | ||
| Missing | 0 | ||
| Tumor type | |||
| Invasive ductal carcinoma | 291 (92.4%) | ||
| Invasive lobular carcinoma | 19 (6.1%) | ||
| Special type colloid and medullary carcinoma | 5 (1.5%) | ||
| Missing | 0 | ||
| Tumor size | |||
| T1 <2 cm in diameter | 32 (10.5%) | ||
| T2 ∼2–5 cm in diameter | 201 (66.1%) | ||
| T3 >5 cm in diameter | 53 (17.4%) | ||
| T4 fixed to chest wall | 18 (5.9%) | ||
| Missing | 11 | ||
| Histological grade | |||
| I | 73 (25.8%) | ||
| II | 138 (48.8%) | ||
| III | 72 (25.4%) | ||
| Missing | 32 | ||
| Involved lymph nodes | 108 (46.8%) | 123 (53.2%) | 84 |
| ERα staining | 166 (39.3%) | 142 (60.7%) | 7 |
| PgR staining | 115 (38.3%) | 185 (61.7%) | 15 |
| AGR2 staining | 208 (66%) | 107 (34%) | 0 |
| C-erbB-2 staining | 71 (23%) | 238 (77%) | 6 |
| C-erbB-3 staining | 180 (59.2%) | 124 (40.8%) | 11 |
| S100A4 staining | 126 (40.3%) | 187 (59.7%) | 2 |
| S100P staining | 147 (53.3%) | 129 (46.7%) | 39 |
| p53 staining | 124 (39.6%) | 189 (60.4%) | 2 |
| Cathepsin D staining | 201 (82.4%) | 43 (17.6%) | 71 |
| pS2 staining | 129 (41.6%) | 181 (58.4%) | 5 |
| Osteopontin staining | 202 (67.1%) | 99 (32.9%) | 14 |
Tumor variables and cutoffs used in immunocytochemical staining to separate the two categorical groups are described in Materials and Methods.